Additionally, CAR-NK cells have emerged as a promising alternative to CAR-T cells for AML treatment due to their innate cytotoxicity and secretion of high levels of interleukins, particularly interferon gamma (IFN-γ) [93]. This evidence concerns the gene IFNG and acute myeloid leukemia.